We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $22 · 1 analysts
Stored first · Google News · Yahoo Finance (English)
Seres Therapeutics (MCRB) Q1 2026 Earnings: EPS Misses Estimates as Stock Declines 8.1% - Dividend Earnings Report - dars.gov.et
Seres Therapeutics (MCRB) Q1 2026 Earnings: EPS Misses Estimates as Stock Declines 8.1% - Dividend Earnings Report dars.gov.et
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com Investing.com Nigeria
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com UK
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com Investing.com UK
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 Stock Titan
Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14 - Stock Titan
Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14 Stock Titan
Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer - Stock Titan
Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $-2.3 | — | — | $360 | — | Scheduled |
| FY2025 Q3 | 2025. 09. 30. | Time TBD | — | $2.1 | — | — | $351K | Reported |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $3.75 | — | — | $0 | Reported |
| FY2024 Q2 | 2023. 06. 30. | Time TBD | — | $-0.19 | — | — | $125.95M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 14. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2025. 09. 24. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2025. 05. 08. | Chardan Capital | — | Downgrade | Buy → Neutral | — | Chardan Capital: Buy → Neutral |
| 2025. 03. 21. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2025. 03. 15. | Goldman Sachs | — | Maintain | Sell → Sell | — | Goldman Sachs: Sell |
| 2024. 11. 15. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 25,749 | $383.15K | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 18,794 | $166.7K | 0.00% | — | New position |